NERV - Minerva Neurosciences, Inc.
| Previous Close | 7.34 |
| Open | 7.44 |
| Bid | 0.00 x 900 |
| Ask | 9.90 x 1300 |
| Day's Range | 7.11 - 7.44 |
| 52 Week Range | 5.00 - 12.95 |
| Volume | 145,140 |
| Avg. Volume | 198,130 |
| Market Cap | 277.542M |
| Beta (3Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks•last month
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- Thomson Reuters StreetEvents•last month
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•last month
Minerva Neurosciences: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
- Simply Wall St.•2 months ago
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks•3 months ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•4 months ago
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•5 months ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of NERV earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•8 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 32 cents. Minerva Neurosciences shares have risen 14 percent since the beginning of the year. The stock has fallen nearly ...
- Zacks•9 months ago
Will Minerva Neurosciences (NERV) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Minerva Neurosciences, Inc. (NERV).
- Thomson Reuters StreetEvents•9 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-18 12:30pm GMT
Q4 2017 Minerva Neurosciences Inc Earnings Call
- Associated Press•9 months ago
Minerva Neurosciences posts 4Q profit
The Waltham, Massachusetts-based company said it had net income of less than 1 cent on a per-share basis. Losses, adjusted for pretax gains, were 24 cents per share. For the year, the company reported ...
- Zacks•last year
Minerva Initiates Phase III Study on Schizophrenia Candidate
Minerva Neurosciences (NERV) initiates a phase III study to evaluate MIN-101 as monotherapy to treat negative symptoms in schizophrenia patients.
